ADARx Pharmaceuticals (ADRX) vs MBX Biosciences (MBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MBX Biosciences is the larger company by market cap ($2.53 billion vs $1.87 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | MBX |
|---|---|---|
| Share price | $17.55 | $52.53 |
| Market cap | $1.87B | $2.53B |
| 1-day change | +1.27% | -3.69% |
| YTD return | — | +72.92% |
| 1-year return | — | +245.19% |
| EPS (TTM) | $-1.16 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-87.00M |
| 52-week high | $23.21 | $72.64 |
| 52-week low | $16.64 | $12.94 |
| Distance from 52-week high | -24.39% | -27.68% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +79.52% |
| Average volume | 1.34M | 539.34K |
| Shares outstanding | 106.80M | 48.16M |
| Employees | 100 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
ADRX vs MBX FAQ
Which is bigger, ADARx Pharmaceuticals or MBX Biosciences?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.53B compared with $1.87B for ADARx Pharmaceuticals (ADRX).
Are ADARx Pharmaceuticals and MBX Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.